Wellington Management Group LLP acquired a new stake in shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Free Report) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 194,108 shares of the company's stock, valued at approximately $2,912,000. Wellington Management Group LLP owned approximately 0.80% of Artiva Biotherapeutics at the end of the most recent quarter.
A number of other hedge funds also recently bought and sold shares of the company. BNP Paribas Financial Markets purchased a new position in shares of Artiva Biotherapeutics during the third quarter worth approximately $42,000. MetLife Investment Management LLC bought a new position in shares of Artiva Biotherapeutics during the 3rd quarter valued at $135,000. Charles Schwab Investment Management Inc. bought a new position in shares of Artiva Biotherapeutics during the 3rd quarter valued at $623,000. Acuta Capital Partners LLC purchased a new position in Artiva Biotherapeutics in the 3rd quarter worth $680,000. Finally, State Street Corp bought a new stake in Artiva Biotherapeutics in the third quarter worth $1,337,000.
Analyst Ratings Changes
ARTV has been the topic of a number of recent research reports. Wedbush reaffirmed an "outperform" rating and set a $18.00 price objective on shares of Artiva Biotherapeutics in a research note on Friday, August 30th. Needham & Company LLC restated a "buy" rating and set a $23.00 price target on shares of Artiva Biotherapeutics in a research report on Wednesday, November 13th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $21.25.
View Our Latest Analysis on Artiva Biotherapeutics
Artiva Biotherapeutics Stock Down 9.7 %
Artiva Biotherapeutics stock traded down $1.07 during trading hours on Wednesday, reaching $9.97. The stock had a trading volume of 46,764 shares, compared to its average volume of 119,634. The company's fifty day simple moving average is $11.81. Artiva Biotherapeutics, Inc. has a 52 week low of $9.68 and a 52 week high of $17.31.
Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report) last posted its earnings results on Tuesday, November 12th. The company reported ($0.92) earnings per share for the quarter, missing analysts' consensus estimates of ($0.68) by ($0.24). As a group, sell-side analysts expect that Artiva Biotherapeutics, Inc. will post -4.68 earnings per share for the current fiscal year.
About Artiva Biotherapeutics
(
Free Report)
Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.
Further Reading
Before you consider Artiva Biotherapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Artiva Biotherapeutics wasn't on the list.
While Artiva Biotherapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
